Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
PODD · Nasdaq · Healthcare
Fundamental quality
88
out of 100
Insulet Corp grows profitably: it increases revenue at double digits (24.9% a year) without giving up profitability (net margin 10.4%). On fundamental quality it scores 88 out of 100, profiling it as a company with solid fundamentals. Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Insulet makes the Omnipod, the tubeless insulin pump: a disposable patch that delivers insulin continuously, controlled from a phone. Every patient constantly uses and discards pods — the recurring-revenue dream applied to diabetes.
EPS growth: 104.6% · Revenue growth: 24.9%
Net margin: 10.4% · ROE: 23.2% · ROIC: 21.4%
Net debt/EBITDA: 0.78x · FCF: 14.3%
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength, and here its pillars hold up evenly.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 904 | 7 | -45 | 152 |
| 2021 | 1,099 | 17 | -180 | 468 |
| 2022 | 1,305 | 5 | -4 | 712 |
| 2023 | 1,697 | 206 | 70 | 712 |
| 2024 | 2,072 | 418 | 305 | 427 |
| 2025 | 2,708 | 247 | 378 | 233 |
Between 2020 and 2025, revenue went from $904M to $2,708M (+199%) and net income went from $7M to $247M (+3534%). Meanwhile, its margins have widened (from 1% to 9%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the quarter ended March 31, 2026, versus the quarter ended March 31, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Insulet Corp cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Insulet Corp a good company to invest in?
In terms of business quality, Insulet Corp scores 88 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Insulet Corp a profitable company?
Yes. Insulet Corp shows a net margin of 10.4% and an ROE of 23.2%, a sign of a profitable business.
Does Insulet Corp have a lot of debt?
Not particularly. Its net debt is 0.78 times its EBITDA, a low level.
Is Insulet Corp growing?
Its revenue has grown 24.9% annualized in recent years and its earnings per share 104.6%, and without interruption since 2020.
Does Insulet Corp generate cash?
Yes. It converts about 14.3% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Agilent Technologies (A) · ResMed (RMD) · West Pharmaceutical (WST) · Mettler-Toledo (MTD) · Waters (WAT) · Biogen (BIIB) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Insulet Corp's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.